Corrigendum to "Interaction of AT1 receptors and V1a receptors-mediated effects in the central cardiovascular control during the post-infarct state" [Regul Pept 142 (2007) 86-94] (DOI:10.1016/j.regpep.2007.01.010);Interaction of AT1 receptors and V1a receptors-mediated effects in the central cardiovascular control during the post-infarct state

Regulatory Peptides

Volumn 142, Issue 3, 2007, Pages 86-94

  Cudnoch Jedrzejewska, Agnieszka ^a   Dobruch, Jakub ^a   Puchalska, Liana ^a   Szczepańska Sadowska, Ewa ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiotensin II; Heart failure; Myocardial infarct; Vasopressin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; LOSARTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; HEART INFARCTION; HEART RATE; HORMONE RECEPTOR INTERACTION; INFUSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; STRESS;

RATTUS;

EID: 34250223435     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.06.009     Document Type: Erratum

References (54)

1. Cowley A.W., Quillen E.W., and Skelton M.M. Role of vasopressin in cardiovascular regulation. Fed. Proc. 42 (1983) 3170-3176
2. Ganten D., Unger Th., and Lang R.E. The dual role of angiotensin and vasopressin as plasma hormones and neuropeptides in cardiovascular regulation. J. Pharmacol. 16 suppl II (1985) 51-68
3. Martin S.M., Malkinson T.J., Veale W.L., and Pittman Q.J. The action of centrally administered arginine vasopressin on blood pressure in the conscious rabbits. Brain Res. 348 (1985) 137-145
4. Robinson M.M., McLean G.P., Thurnhorst R.L., and Johnson A.K. Interactions of the systemic and brain renin-angiotensin systems in the control of drinking and the central mediation of pressor responses. Brain Res. 842 (1999) 55-61
5. Szczepańska-Sadowska E. Interaction of vasopressin and angiotensin II in central control of blood pressure and thirst. Regul. Pept. 66 (1996) 65-71
6. DiBona G.F. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J. Am. Soc. Nephrol. Suppl. 11 (1999) S90-S94
7. Noszczyk B., Łoń S., and Szczepańska-Sadowska E. Central cardiovascular effects of AVP and AVP analogs with V1, V2 and V3 agonistic or antagonistic properties in conscious dog. Brain Res. 610 (1993) 115-126
8. Toney G.M., and Porter J.P. Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats. Neuropharmacology 32 (1993) 581-589
9. Janiak P., Kasson B.G., and Brody M.J. Central vasopressin raises arterial pressure by sympathetic activation and vasopressin release. Hypertension 13 (1989) 935-940
10. Łoń S., Szczepańska-Sadowska E., and Szczypaczewska M. Evidence that centrally released arginine vasopressin is involved in central pressor action of angiotensin II. Am. J. Physiol. Heart Circ. Physiol. 270 (1996) H167-H173
11. Szczepańska-Sadowska E., Paczwa P., Łoń S., and Ganten D. Increased pressor function of central vasopressinergic system in hypertensive renin transgenic rats. J. Hypertens. 16 (1998) 1505-1514
12. DiBona G.F., Jones S.Y., and Brooks V.L. Ang II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. Am. J. Physiol., Regul. Integr. Comp. Physiol. 269 (1995) R1189-R1196
13. Felder R.B., Francis J., Zhang Z.H., Wei S.G., Weiss R.M., and Johnson A.K. Heart failure and brain: new perspectives. Am. J. Physiol., Regul. Integr. Comp. Physiol. 284 (2003) R259-R276
14. Naitoh M., Suzuki H., Murakami M., Matsumoto A., Arakawa K., Ichihara A., Nakamoto H., Oka K., Yamamura Y., and Saruta T. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. Heart Circ. Physiol. 267 (1994) H2245-H2254
15. Zhang W., Huang B.S., and Leenen F.H.H. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 276 (1999) H1608-H1615
16. Zucker I.H., Wang W., Rainer U., Pliquett R.U., Liu J.L., and Patel K.P. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann. N.Y. Acad. Sci. 940 (2001) 431-443
17. Wang H., Huang B.S., Ganten D., and Leenen F.H. Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circ. Res. 94 (2004) 843
18. Zhu G.Q., Gao L., Li Y., Patel K.P., Zucker I.H., and Wang W. AT1 receptor mRNA antisense normalizes enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1828-H1835
19. Zhu G.Q., Gao L., Patel K.P., Zucker I.H., Wang W., Zucker I.H., and Wang W. Ang II in the paraventricular nucleus potentates the cardiac sympathetic afferent reflex in rats with heart failure. J. Appl. Physiol. 97 (2004) 1746-1754
20. Dobruch J., Cudnoch-Je{ogonek}drzejewska A., and Szczepańska-Sadowska E. Enhanced involvement of brain vasopressin V1 receptors in cardiovascular responses to stress in rats with myocardial infarction. Stress 8 (2005) 273-284
21. Budzikowski A., Paczwa P., and Szczepanska-Sadowska E. Central V1AVP receptors are involved in cardiovascular adaptation to hypovolemia in WKY but not in SHR. Am. J. Physiol. 271 (1996) H1057-H1064
22. Ferguson A.V., and Washburn D.L.S. Angiotensin II: a peptidergic neurotransmitter in central autonomic pathways. Prog. Neurobiol. 54 (1998) 169-192
23. Flynn F.W., Kirchner T.R., and Clinton M.E. Brain vasopressin and sodium appetite. Am. J. Physiol., Regul. Integr. Comp. Physiol. 282 (2002) R1236-R1244
24. Landgraf R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol. Disord. Drug Targets 5 (2006) 167-179
25. Phillips M.I., and Sumners C. Angiotensin II in central nervous system physiology. Regul. Pept. 78 (1998) 1-13
26. Saavedra J.M., Ando H., Armando I., Baiardi G., Bregonzio C., Juorio A., and Macova M. Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul. Pept. 128 (2005) 227-238
27. Saiki Y., Watanabe T., Tan N., Matsuzaki M., and Nakamura S. Role of central ANG II receptors in stress-induced cardiovascular and hyperthermic responses in rats. Am. J. Physiol. 272 (1997) R26-R33
28. Wright J.W., and Harding J.W. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci. Biobehav. Rev. 18 (1994) 21-53
29. Armando I., Carranza A., Nishimura Y., Hoe K.-L., Barontini M., Terron J.A., Falcon-Neri A., Ito T., Juorio A.V., and Saavedra JM. Peripheral administration of an angiotensin II AT1 receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology 142 (2001) 3880-3889
30. Wang J.M., Tan J., and Leenen F.H. Central nervous system blockade by peripheral administration of AT1 receptor blockers. J. Cardiovasc. Pharmacol. 41 (2003) 593-599
31. Selye H., Bajusz E., Grasso S., and Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11 (1960) 398-407
32. Leenen F.H.H., Yuan B., and Huang B.S. Brain "ouabain" and angiotensin II contribute to cardiac dysfunction after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 277 (1999) H1786-H1792
33. Cudnoch-Je{ogonek}drzejewska A., Szczepańska-Sadowska E., Dobruch J., Morton M., Koperski Ł., Wasiutyński A., Wsół A., and Kowalewski S. Fluid consumption, electrolyte excretion and heart remodeling in rats with myocardial infarct maintained on regular and high sodium intake. J. Physiol. Pharmacol. 56 (2005) 599-610
34. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 28 (1994) 303-311
35. Curran-Everett D., and Benos D.J. Guidelines for reporting statistics in journals published by the American Physiological Society. Physiol. Genomics 18 (2004) 249-251
36. Ufnal M., Dudek M., Żera T., and Szczepańska-Sadowska E. Centrally administered interleukin-1beta sensitizes to the central pressor action of angiotensin II. Brain Res. 1100 (2006) 64-72
37. Armando I., Seltzer A., Bregonzio C., and Saavedra J.M. Stress and angiotensin II: novel therapeutic opportunities. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 413-419
38. Mayorov D.N., and Head G.A. AT1 receptors in the RVLM mediate pressor responses to emotional stress in rabbits. Hypertension 41 (2003) 1168-1173
39. Saavedra J.M., Ando H., Armando I., Baiardi G., Bregonzio C., Jezova M., and Zhou J. Brain angiotensin II, an important stress hormone: regulatory sites and therapeutic opportunities. Ann. N.Y. Acad. Sci. 1018 (2004) 76-84
40. Saavedra J.M., Armando I., Bregonzio C., Juorio A., Macova M., Pavel J., and Sanchez-Lemus E. A centrally acting anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology 31 (2006) 1123-1134
41. Salchner P., Sartori S.B., Sinner C., Wigger A., Frank E., Landgraf R., and Singewald N. Airjet and FG-7142-induced Fos expression differs in rats selectively bred for high and low anxiety-related behavior. Neuropharmacology 50 (2006) 1048-1058
42. Stojic S., Miltunovic S., Sarenac O., Zivkovic S., and Japundzic-Zigon N. Central vasopressin V1a and V1b receptors modulate the cardiovascular response to air-jet stress in conscious rats. Biomed. Tech. (Berl) 51 (2006) 268-271
43. De Matteo R., Head G.A., and Mayorov D.N. Angiotensin II in dorsomedial hypothalamus modulates cardiovascular arousal caused by stress but not feeding in rabbits. Am. J. Physiol., Regul. Integr. Comp. Physiol. 290 (2006) R257-R264
44. Singewald N., Kaehler S.T., and Philippu A. Noradrenaline release in the locus coeruleus of conscious rats is triggered by drugs, stress and blood pressure. NeuroReport 14 (1999) 1583-1587
45. Phillips M.I., Shen I., and Richard E.M. Immunohistochemical mapping of angiotensin AT1 receptors in the brain. Regul. Pept. 44 (1993) 95-107
46. Tan J., Wang H., and Leenen F.H.H. Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats. Am. J. Physiol, Heart Circ. Physiol. 286 (2004) H1665-H1671
47. Tribollet E., Raufaste D., Maffrand J.P., and Serradeil-Le Gal C. Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocrinology 69 (1999) 113-120
48. Mansi J.A., Laforest S., and Drolet G. Effect of stress exposure on the activation pattern of enkephalin-containing parikarya in the rat ventral medulla. J. Neurochem. 74 (2000) 2568-2575
49. Nalivaiko E., Ootsyuka Y., and Blessing W.W. Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stress in rabbits. Am. J. Physiol., Regul. Integr. Comp. Physiol. 289 (2005) R596-R604
50. Mayorov D.N., Head G.A., and De Matteo R. Tempol attenuates excitatory actions of angiotensin II in the rostral ventrolateral medulla during emotional stress. Hypertension 44 (2004) 101-106
51. Hu K., Bahner U., Gaudron P., Palkovits M., Ring M., Fehle A., Kruse B., and Ertl G. Chronic effects of ACE-inhibition (quinapril) and angiotensin-II-type 1 receptor blockade (losartan) on atrial natriuretic peptide in brain nuclei of rats with experimental myocardial infarction. Basic Res. Cardiol. 96 (2001) 258-266
52. Shirakami G., Nakao K., Yamada T., Itoh H., Mori K., Kangawa K., Minamino N., Matsuo H., and Imura H. Inhibitory effect of brain natriuretic peptide on central angiotensin II-stimulated pressor response in conscious rats. Neurosci. Lett. 91 (1988) 77-83
53. Ste{ogonek}pniakowski K., Budzikowski A., Łoń S., and Szczepańska-Sadowska E. Central ANP attenuates pressor response to central AVP in WKY and SHR. Brain Res. Bull. 27 (1991) 247-249
54. Griebel G., Simand J., Stemmelin J., Gal C.S., and Steinberg R. The vasopressin V1b receptor as therapeutic target in stress-related disorders. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 191-200